These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice. Qin Y; Wang XH; Cui HL; Cheung YK; Hu MH; Zhu SG; Xie Y Gynecol Oncol; 2005 Feb; 96(2):475-83. PubMed ID: 15661238 [TBL] [Abstract][Full Text] [Related]
5. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264 [TBL] [Abstract][Full Text] [Related]
6. Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein. Hallez S; Brulet JM; Vandooren C; Maudoux F; Thomas S; Heinderickx M; Bollen A; Wattiez R; Jacquet A Anticancer Res; 2004; 24(4):2265-75. PubMed ID: 15330171 [TBL] [Abstract][Full Text] [Related]
7. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947 [TBL] [Abstract][Full Text] [Related]
8. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Préville X; Ladant D; Timmerman B; Leclerc C Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409 [TBL] [Abstract][Full Text] [Related]
9. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969 [TBL] [Abstract][Full Text] [Related]
10. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Fernando GJ; Stewart TJ; Tindle RW; Frazer IH J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239 [TBL] [Abstract][Full Text] [Related]
11. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002 [TBL] [Abstract][Full Text] [Related]
12. DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44-60). Pokorna D; Cerovska N; Smahel M; Moravec T; Ludvikova V; Mackova J; Synkova H; Duskova M; Hozak P; Veleminsky J Oncol Rep; 2005 Oct; 14(4):1045-53. PubMed ID: 16142370 [TBL] [Abstract][Full Text] [Related]
13. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Velders MP; McElhiney S; Cassetti MC; Eiben GL; Higgins T; Kovacs GR; Elmishad AG; Kast WM; Smith LR Cancer Res; 2001 Nov; 61(21):7861-7. PubMed ID: 11691804 [TBL] [Abstract][Full Text] [Related]
14. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807 [TBL] [Abstract][Full Text] [Related]
15. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018 [TBL] [Abstract][Full Text] [Related]
16. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417 [TBL] [Abstract][Full Text] [Related]
18. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
19. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Dell K; Klein C; Gissmann L Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528 [TBL] [Abstract][Full Text] [Related]
20. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Daemen T; Regts J; Holtrop M; Wilschut J Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]